Inclusion bodies (IBs) are often produced during overexpression of recombinant proteins in
E. coli. These were initially perceived as amorphous aggregates of misfolded (and hence …

Abstract Background Bacterial inclusion bodies (IBs) are key intermediates for protein
production. Their quality affects the refolding yield and further purification. Recent functional …

Human G‐CSF (granulocyte colony‐stimulating factor) is a well‐known biopharmaceutical
drug being mostly produced by overexpression in Escherichia coli, where it appears in the …

The demand for large-scale production of pure and functional proteins via cost-effective and
simple methods is highly emerging at present. In biotechnology, proteins are synthesized in …

Overexpression of foreign proteins in Escherichia coli often leads to the formation of
inclusion bodies (IBs), which becomes the major bottleneck in the preparation of …

Four decades have passed since the first recombinant protein, somatostatin, was produced
in Escherichia coli. To date, more than 160 biopharmaceuticals gained medical approval. As …

Overexpression of cloned or synthetic genes in Escherichia coli often results in the formation
of insoluble protein inclusion bodies. Within the last decade, specific methods and strategies …

Christian Anfinsen's successful renaturation of reduced, unfolded ribonuclease in 1957
paved the way for protein folding to become a major topic in biochemical research (1). The …

Background Recombinant protein expression in bacteria often leads to the formation of
intracellular insoluble protein deposits, a major bottleneck for the production of soluble and …

A common limitation of recombinant protein production in bacteria is the formation of
insoluble protein aggregates known as inclusion bodies. The propensity of a given protein to …